X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs DISHMAN PHARMA - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA DISHMAN PHARMA GLENMARK PHARMA/
DISHMAN PHARMA
 
P/E (TTM) x 23.1 25.1 92.2% View Chart
P/BV x 3.2 3.3 94.2% View Chart
Dividend Yield % 0.3 0.7 50.2%  

Financials

 GLENMARK PHARMA   DISHMAN PHARMA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
DISHMAN PHARMA
Mar-16
GLENMARK PHARMA/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs930374 248.4%   
Low Rs517129 401.4%   
Sales per share (Unadj.) Rs322.6197.8 163.1%  
Earnings per share (Unadj.) Rs28.521.2 134.3%  
Cash flow per share (Unadj.) Rs39.234.7 112.9%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.30.8 34.8%  
Book value per share (Unadj.) Rs183.0179.9 101.7%  
Shares outstanding (eoy) m282.1780.69 349.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.21.3 176.3%   
Avg P/E ratio x25.411.9 214.1%  
P/CF ratio (eoy) x18.57.2 254.8%  
Price / Book Value ratio x4.01.4 282.7%  
Dividend payout %7.09.4 74.4%   
Avg Mkt Cap Rs m204,20620,306 1,005.7%   
No. of employees `00013.70.8 1,654.5%   
Total wages/salary Rs m18,7185,355 349.6%   
Avg. sales/employee Rs Th6,636.819,252.7 34.5%   
Avg. wages/employee Rs Th1,364.76,459.5 21.1%   
Avg. net profit/employee Rs Th586.12,064.1 28.4%   
INCOME DATA
Net Sales Rs m91,03115,961 570.3%  
Other income Rs m914265 344.4%   
Total revenues Rs m91,94516,226 566.7%   
Gross profit Rs m16,1544,103 393.7%  
Depreciation Rs m3,0191,091 276.8%   
Interest Rs m2,856944 302.4%   
Profit before tax Rs m11,1932,334 479.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,155624 505.9%   
Profit after tax Rs m8,0391,711 469.8%  
Gross profit margin %17.725.7 69.0%  
Effective tax rate %28.226.7 105.5%   
Net profit margin %8.810.7 82.4%  
BALANCE SHEET DATA
Current assets Rs m69,88711,018 634.3%   
Current liabilities Rs m32,8799,517 345.5%   
Net working cap to sales %40.79.4 432.3%  
Current ratio x2.11.2 183.6%  
Inventory Days Days81110 73.7%  
Debtors Days Days9335 268.4%  
Net fixed assets Rs m28,89216,304 177.2%   
Share capital Rs m282161 174.8%   
"Free" reserves Rs m51,35312,907 397.9%   
Net worth Rs m51,63514,516 355.7%   
Long term debt Rs m41,4184,189 988.6%   
Total assets Rs m125,95429,805 422.6%  
Interest coverage x4.93.5 141.7%   
Debt to equity ratio x0.80.3 277.9%  
Sales to assets ratio x0.70.5 135.0%   
Return on assets %8.68.9 97.1%  
Return on equity %15.611.8 132.1%  
Return on capital %15.117.5 86.1%  
Exports to sales %024.8 0.0%   
Imports to sales %03.7 0.0%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs mNA596 0.0%   
Fx inflow Rs m36,3174,952 733.5%   
Fx outflow Rs m9,720697 1,394.9%   
Net fx Rs m26,5984,255 625.1%   
CASH FLOW
From Operations Rs m16,4812,786 591.5%  
From Investments Rs m-10,133-1,529 662.8%  
From Financial Activity Rs m-4,685-941 497.8%  
Net Cashflow Rs m1,770316 559.4%  

Share Holding

Indian Promoters % 48.3 61.4 78.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 3.7 186.5%  
FIIs % 34.4 12.7 270.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 22.1 47.5%  
Shareholders   56,727 46,261 122.6%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   CADILA HEALTHCARE  J.B.CHEMICALS  ORCHID PHARMA LTD  STRIDES SHASUN LTD  FULFORD INDIA  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 383 Points Lower; Realty and Auto Stocks Drag(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 27, 2018 | Updated on Sep 27, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 30.1% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 30.1% YoY). Sales on the other hand came in at Rs 22 bn (down 8.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Don't Panic in This Falling Market... Do This Instead(The 5 Minute Wrapup)

Oct 5, 2018

Find companies with long term durable moats, which are correcting with the current broader market sell-off.

Taxpayers to pay salaries of CEOs/CIOs of Mutual Funds(The Honest Truth)

Oct 5, 2018

Ajit Dayal on the crisis in the market and in the mutual fund industry.

This Market Crash could be the Biggest Wealth Creating Opportunity Since 2008(Profit Hunter)

Oct 8, 2018

While widespread fear is the friend of a value investor, serving up bargain purchases; personal fear is an investor's biggest enemy.

IPO Market Feels the Heat of the Market Crash(Sector Info)

Oct 12, 2018

The sentiments in primary market have also deteriorated amid the stock market correction. Most listed IPOs of 2018 are trading below their issue price.

Are These Deep Corrections a Buying Signal?(Chart Of The Day)

Oct 5, 2018

The correction has bought many good companies to reasonable valuations. Go against the wisdom of crowd and Buy.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Oct 17, 2018 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS